Financiere des Professionnels Fonds d investissement inc. Has $4.89 Million Holdings in Boston Scientific Corporation $BSX

Financiere des Professionnels Fonds d investissement inc. lessened its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 28.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 45,564 shares of the medical equipment provider’s stock after selling 18,247 shares during the period. Financiere des Professionnels Fonds d investissement inc.’s holdings in Boston Scientific were worth $4,894,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the business. Thrive Wealth Management LLC acquired a new position in shares of Boston Scientific during the second quarter worth $787,000. New England Research & Management Inc. acquired a new position in shares of Boston Scientific during the second quarter worth $1,133,000. Bank of New Hampshire lifted its holdings in shares of Boston Scientific by 552.0% during the second quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock worth $2,119,000 after purchasing an additional 16,699 shares during the period. Central Bank & Trust Co. lifted its holdings in shares of Boston Scientific by 30.5% during the second quarter. Central Bank & Trust Co. now owns 10,759 shares of the medical equipment provider’s stock worth $1,156,000 after purchasing an additional 2,517 shares during the period. Finally, Czech National Bank lifted its holdings in shares of Boston Scientific by 6.8% during the second quarter. Czech National Bank now owns 361,629 shares of the medical equipment provider’s stock worth $38,843,000 after purchasing an additional 23,011 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Trading Down 0.9%

NYSE:BSX opened at $98.97 on Wednesday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The firm has a 50-day moving average of $104.71 and a 200-day moving average of $102.22. The company has a market cap of $146.65 billion, a PE ratio of 58.91, a PEG ratio of 2.40 and a beta of 0.65. Boston Scientific Corporation has a one year low of $80.64 and a one year high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the previous year, the company earned $0.62 earnings per share. The firm’s revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on BSX shares. Barclays lifted their price target on shares of Boston Scientific from $125.00 to $133.00 and gave the stock an “overweight” rating in a report on Thursday, July 24th. Leerink Partners assumed coverage on shares of Boston Scientific in a report on Monday, June 16th. They issued an “outperform” rating and a $118.00 target price on the stock. Leerink Partnrs upgraded shares of Boston Scientific to a “strong-buy” rating in a report on Monday, June 16th. Wells Fargo & Company boosted their target price on shares of Boston Scientific from $118.00 to $124.00 and gave the company an “overweight” rating in a report on Thursday, July 24th. Finally, UBS Group boosted their target price on shares of Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a report on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Buy” and a consensus target price of $118.04.

Insider Activity

In related news, Director Edward J. Ludwig sold 4,000 shares of the business’s stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the transaction, the director directly owned 18,479 shares in the company, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $18,659,923.46. This trade represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock valued at $18,397,457 in the last three months. 0.50% of the stock is owned by company insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.